ARE

Analyst Note: Alexandria Real Estate Equities, Inc. (ARE)

Date: 2026-06-13 Current Price: $51.03

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 4.2% (High)

Analysis:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None Named.

At this date, ARE is classified as a TACTICAL, setup-led name. There is no named secular macro thesis driving the immediate conviction stack. The investment case must be judged strictly on the quality of the structural setup (which is currently absent) and the underlying business fundamentals. No external macro drivers (e.g., specific interest rate regime shifts or biotech funding surges) are explicitly named in the evidence base as the primary catalyst for this specific date. The analysis relies entirely on the company's operational execution and financial guidance.

3. Business Overview

Company: Alexandria Real Estate Equities, Inc. (ARE) Industry: Real Estate Investment Trust (REIT) — Life Science Business Model: ARE operates as the preeminent owner, operator, and developer of collaborative "Megacampus" ecosystems in premier life science innovation clusters. The company focuses on Class A/A+ laboratory and office space tailored for life science, technology, and agtech sectors.

Key Operational Metrics (as of source dates ≤ 2026-06-13):

• Portfolio Scale: As of December 31, 2025, the company held 340 properties in North America, comprising approximately 39.4 million RSF of operating properties and new development/redevelopment projects under construction (Evidence E15).
• Occupancy: Operating property occupancy in North America was 90.9% as of December 31, 2025. This is below the company's 10-year average of 95% (Evidence E12).
• Development Pipeline: The company has 1.9 million square feet of projects under construction. Of this, 77% is leased. Approximately 600,000 square feet is expected to stabilize in 2026, with a 93% lease rate (Evidence E3).
• Tenant Quality: 55% of annual rental revenue is derived from investment-grade or publicly traded large-cap tenants (Evidence E4). Tenants include multinational pharmaceutical companies, biotechnology firms, and U.S. government institutions (Evidence E8, E11).
• Leasing Strategy: Management noted a shift in leasing activity, stating, "This is maybe the first quarter in the history of the company that I can remember where we didn't sign a single public biotech lease" (Evidence E5).
• Capital Discipline: The company generally does not commence new aboveground construction without significant pre-leasing, except when solid market demand exists (Evidence E14).
• Funding Strategy: ARE plans to fund a significant portion of 2026 capital requirements through dispositions of land, non-core assets, and core assets (Evidence E10).
• Turnover: Voluntary and total turnover rates averaged 4.6% and 9.3% respectively from 2021 to 2025, significantly below REIT industry averages of 12.0% and 17.0% (Evidence E16).

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: ARE fits the Quality Compounder archetype based on its long-tenured status (founded 1994), its dominance in the life science niche, and its superior tenant retention metrics compared to industry averages. The company's focus on "Megacampus" ecosystems in AAA locations (Boston, SF Bay, San Diego, etc.) provides a structural moat (Evidence E9, E13).

Valuation and Financial Context:

• Guidance: Management reaffirmed the midpoint of guidance for 2026 FFO per share diluted as adjusted at $6.40, tightening the range (Evidence E2).
• Completion Expectations: Management expects a weighted average completion date of August 2026 for current projects, noting this is about a month later than initial Investor Day guidance (Evidence E7).
• Financial Spine: Forward consensus EPS for FY1 is 1.85, while FY2 shows a consensus of -0.19 (Evidence E22). This divergence suggests a potential earnings compression or restructuring in the second year of the forecast, which is a critical data point for the "Quality Compounder" thesis.
• Conviction Stack:
• *Thesis Strength:* Low (No named macro thesis).
• *Evidence Quality:* High (Strong operational data, clear guidance, low turnover).
• *Structural Quality:* N/A (No setup defined).
• *Setup Readiness:* None (Context-only).
• *Rerating Potential:* Dependent on the successful stabilization of the 600k sq ft pipeline in 2026 and the resolution of the FY2 earnings outlook.

The current ATR of 4.2% (High) indicates elevated volatility, which is typical for REITs in transition or during periods of significant capital deployment. However, without a defined structural entry, this volatility is a sizing parameter for future setups rather than a current signal.

5. Invalidations, Strengtheners, and Gaps

Invalidation Factors:

• A sustained drop in occupancy below the 90.9% level recorded in Dec 2025, particularly if driven by an inability to lease the 1.9 million sq ft under construction.
• Failure to meet the reaffirmed 2026 FFO guidance of $6.40 per share.
• A significant increase in tenant turnover rates approaching or exceeding the industry average of 17.0%.

Strengtheners:

• Successful stabilization of the 600,000 sq ft expected in 2026 at the projected 93% lease rate.
• Successful execution of asset dispositions to fund capital requirements without diluting equity.
• Reversal of the "no public biotech lease" trend, indicating renewed demand from the core biotech sector.

Evidence Gaps:

• Balance Sheet Details: While dispositions are planned, specific debt maturity schedules or leverage ratios for 2026 are not provided in the evidence block.
• FY2 Outlook: The negative consensus EPS for FY2 (-0.19) is a significant gap in understanding the long-term earnings trajectory, though this is a consensus estimate, not management guidance.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management reaffirmed 2026 FFO guidance at $6.40; 93% leased rate on 600k sq ft stabilizing in 2026; turnover rates significantly below industry averages. Key risks: FY2 consensus EPS is negative (-0.19); occupancy at 90.9% is below 10-year average of 95%; no public biotech leases signed in the referenced quarter; no defined technical setup (context-only). Expected path: Management expects 1.9 million sq ft under construction to stabilize through 2028, with 600k sq ft stabilizing in 2026; capital requirements to be funded via asset dispositions. Expected horizon: 12-18 months for stabilization of the 2026 pipeline and resolution of FY2 earnings outlook. Failure mode to watch: Failure to meet the $6.40 FFO guidance or a further decline in occupancy below 90%.